Abcuro is a clinical stage biotechnology company developing treatments for autoimmune and cancer indications modulated by cytotoxic T and NK cells that express the inhibitory immune checkpoint receptor KLRG1 (killer cell lectin-like receptor G1). The company is advancing ABC008, a first-in-class anti-KLRG1 antibody designed to deplete cytotoxic T cells that attack healthy muscle tissue in patients with inclusion body myositis (IBM), into clinical studies. IBM is a progressive and debilitating inflammatory skeletal muscle condition with no available pharmaceutical therapies. Abcuro has received FDA orphan drug designation for ABC008 in IBM. The company is also advancing ABC015, an anti-KLRG1 blocking antibody capable of reactivating inhibited cytotoxic T and NK cells in the tumor microenvironment.
Location: United States, Massachusetts, Newton
Employees: 11-50
Total raised: $397M
Founded date: 2015
Investors 6
| Date | Name | Website |
| - | ShangPharm... | spiivc.com |
| - | Myeloma In... | myelomainv... |
| - | RA Capital... | racap.com |
| 28.05.2024 | Bain Capit... | baincapita... |
| 25.08.2023 | New Leaf V... | nlvpartner... |
| - | Pontifax V... | pontifax.c... |
Funding Rounds 3
| Date | Series | Amount | Investors |
| 19.02.2025 | Series C | $200M | - |
| 18.08.2023 | Series B | $155M | - |
| 07.01.2021 | Series A | $42M | - |
Mentions in press and media 10
| Date | Title | Description |
| 19.02.2025 | Abcuro: $200 Million (Series C) Raised For Advancing Medicine In Development For Inclusion Body Myositis | Abcuro – a clinical-stage biotechnology company developing therapies for the treatment of autoimmune diseases and cancer through precise modulation of cytotoxic T cells – announced the closing of a $200 million Series C financing led by New... |
| 13.02.2025 | Abcuro Raises $200M in Series C Financing | Abcuro, a Newton, MA-based clinical-stage biotechnology company, raised $200M in Series C funding. The round was led by New Enterprise Associates (NEA) joined by Foresite Capital with participation from existing investors including RA Capit... |
| 29.09.2023 | Eurofarma anuncia un fondo de 100M$ para invertir en startups biotechs | Eurofarma, compañía farmacéutica brasileña con presencia en América Latina y EE. UU., ha anunciado el lanzamiento de un fondo corporativo de 100 millones de dólares para invertir en startups del ámbito biotecnológico, que tengan proyectos e... |
| 18.08.2023 | Abcuro Raises $155M in Series B Financing | Abcuro, a Newton, MA-based clinical-stage biotechnology company developing therapies for the treatment of autoimmune diseases and cancer, raised $155M in Series B funding. The round was co-led by Redmile Group and Bain Capital Life Sciences... |
| 17.08.2023 | Sanofi-backed Abcuro loads up with $155M series B to push KLRG1 antibody through clinic | Abcuro will draw on an oversubscribed series B round to continue the journey of its anti-KLRG1 candidate through clinical trials for a muscle disease and cancers. The latest round of $155 million follows a $42 million series A co-led by San... |
| 07.10.2022 | Sanofi's BD chief heads to Owkin as CBO; Roche relies on its bench for Thomas Schinecker’s diagnostics replacement | Alban de La Sablière Up until recently, Alban de La Sablière was Sanofi’s chief dealmaker, reporting directly to CEO Paul Hudson without officially being a C-suite executive. That’s now changed with de La Sablière’s newe... |
| 08.01.2021 | Daily funding roundup - January 8th, 2021 | SilviaTerra raised $4.4M; Hipcamp landed $57M; DiCE Molecules secured $80M; Affinivax picks up $226M SilviaTerra: SilviaTerra is a San Francisco-based forestry company for organizations to exchange carbon offsets. SilviaTerra has raised $4.... |
| 07.01.2021 | Sanofi-backed Abcuro bags $42M to trial KLRG1 immunotherapy | Abcuro has raised $42 million in a Sanofi Ventures co-led series A to advance anti-KLRG1 treatments for autoimmune diseases and cancers. The financing positions a leadership team featuring David de Graaf, Ph.D., and John Edwards to run a pr... |
| 07.01.2021 | Abcuro Raises $42 Million in Series A-1 | NEWTON, Mass.--(BUSINESS WIRE)--Abcuro, Inc., a clinical-stage biotechnology company developing therapies for autoimmune diseases and cancer through precise modulation of cytotoxic T and NK cells, today announced the closing of a $42 millio... |
| - | Abcuro | “Precision Targeting of Highly Cytotoxic T Cells in Autoimmune Disease.” |